Next Article in Journal
Combined Sorafenib and Yttrium-90 Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma
Previous Article in Journal
The Cost-Effectiveness of Bevacizumab for the Treatment of Advanced Ovarian Cancer in Canada
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 5
10.3747/co.23.3108
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Progression Pattern and Adverse Events with Bevacizumab in Glioblastoma

by
A. Mamo
1,
A. Baig
1,
M. Azam
1,
Y.S. Rho
1,
S. Sahebjam
1,
T. Muanza
2,
S. Owen
3,
K. Petrecca
4,
M.C. Guiot
5,
J. Al-Shami
6,
R. Sharma
6 and
P. Kavan
1,*
1
Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada
2
Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada
3
Department of Oncology, McGill University Health Centre, Montreal, QC, Canada
4
Neurosurgery, Montreal Neurological Institute, Montreal, QC, Canada
5
Pathology, McGill University Health Centre, Montreal, QC, Canada
6
Clinical Research, McGill University Health Centre, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(5), 468-471; https://doi.org/10.3747/co.23.3108
Submission received: 14 July 2016 / Revised: 11 August 2016 / Accepted: 10 September 2016 / Published: 1 October 2016

Abstract

Background: The use of bevacizumab in the management of glioblastoma multiforme (gbm) remains controversial. In Canada, bevacizumab is approved for the treatment of recurrent gbm. We describe a pattern of progression across treatment lines in gbm. Methods: During 2008–2014, 64 patients diagnosed with gbm were treated with bevacizumab at McGill University hospitals. Of those patients, 30 (46.9%) received bevacizumab in the first line (B1L), and 34 (53.1%) received it in the second line and beyond (B2L+). The average length of treatment with bevacizumab was 24.4 weeks (range: 0–232.7 weeks). The patterns of progression were categorized as local, distant, diffuse, multifocal, or multi-pattern. Results: Local progression was seen in 46.7% of B1L patients and 26.5% of B2L+ patients, distant in 3.3% and 2.9%, diffuse in 20% and 47%, multifocal in 10% and 8.8%, and multi-pattern in 3.3% and 11.8%. No differences between the groups were observed for the distant (p = 0.3) or diffuse (p = 0.4) patterns. Grades 3 and 4 adverse events in the B1L and B2L+ groups were fatigue (33.3% vs. 17.6% respectively), hypertension (26.7% vs. 5.9%), thrombocytopenia (26.7% vs. 11.8%), neutropenia (26.7% vs. 11.8%), anemia (23.3% vs. 11.8%), leucopenia (20% vs. 8.8%), deep vein thrombosis (23.3% vs. 5.9%), seizure (16.7% vs. 8.8%), brain hemorrhage (6.7% vs. <1%), and delayed wound healing (6.7% vs. 2.9%). More total grades 3 and 4 adverse events occurred in the B1L group (p = 0.000519). Conclusions: In our cohort, patterns of progression were not different in B1L and B2L+ patients. Moreover, both groups experienced similar adverse events, although more grades 3 and 4 events occurred in the B1L group, implying that severe adverse events in B1L patients could negatively affect survival outcomes.
Keywords: glioblastoma multiforme; bevacizumab; patterns of progression; adverse events; survival glioblastoma multiforme; bevacizumab; patterns of progression; adverse events; survival

Share and Cite

MDPI and ACS Style

Mamo, A.; Baig, A.; Azam, M.; Rho, Y.S.; Sahebjam, S.; Muanza, T.; Owen, S.; Petrecca, K.; Guiot, M.C.; Al-Shami, J.; et al. Progression Pattern and Adverse Events with Bevacizumab in Glioblastoma. Curr. Oncol. 2016, 23, 468-471. https://doi.org/10.3747/co.23.3108

AMA Style

Mamo A, Baig A, Azam M, Rho YS, Sahebjam S, Muanza T, Owen S, Petrecca K, Guiot MC, Al-Shami J, et al. Progression Pattern and Adverse Events with Bevacizumab in Glioblastoma. Current Oncology. 2016; 23(5):468-471. https://doi.org/10.3747/co.23.3108

Chicago/Turabian Style

Mamo, A., A. Baig, M. Azam, Y.S. Rho, S. Sahebjam, T. Muanza, S. Owen, K. Petrecca, M.C. Guiot, J. Al-Shami, and et al. 2016. "Progression Pattern and Adverse Events with Bevacizumab in Glioblastoma" Current Oncology 23, no. 5: 468-471. https://doi.org/10.3747/co.23.3108

APA Style

Mamo, A., Baig, A., Azam, M., Rho, Y. S., Sahebjam, S., Muanza, T., Owen, S., Petrecca, K., Guiot, M. C., Al-Shami, J., Sharma, R., & Kavan, P. (2016). Progression Pattern and Adverse Events with Bevacizumab in Glioblastoma. Current Oncology, 23(5), 468-471. https://doi.org/10.3747/co.23.3108

Article Metrics

Back to TopTop